Low-dose aspirin use does not increase disease activity in pregnant patients with Inflammatory Bowel Disease

Abstract

Abstract Background: The adverse effects of nonsteroidal anti-inflammatory (NSAID) drugs on the gastrointestinal system are well recognized, but the effect of NSAID use on disease activity patients with inflammatory bowel disease (IBD) remains unresolved. Low-dose aspirin (LDA) is recommended for all pregnant patients with risk factors for developing preeclampsia, including autoimmune conditions. As recognition of risk factors for preeclampsia improves, the preventative use of LDA is likely to increase. Aims: To investigate if LDA use for prevention of preeclampsia increases the risk of disease activity in pregnant women with IBD. Methods: Single-center retrospective cohort study of pregnant patients with IBD who delivered from 2012-2020, comparing those with and without LDA use. Primary outcome was odds of clinical IBD activity in patients in remission at time of conception. Secondary outcomes were rate of elevated inflammatory biomarkers, defined as C-reactive protein >5 ug/mL or fecal calprotectin >250 ug/g, and rate of preeclampsia. Univariate and multivariate tested for associations. Results: Patients taking LDA were older (p=0.003) and more likely to have chronic hypertension (p=0.002), to have undergone in vitro fertilization (p < 0.001), and to be on biologics (p=0.03). Among patients in remission at conception, there was no difference in clinical disease activity or biomarker elevation during pregnancy based on LDA use (OR 1.27, 95% CI [0.55-2.94], p=0.6). Rates of preeclampsia were similar between groups. Conclusion: LDA use for preeclampsia prevention did not increase the incidence of IBD activity in pregnant patients with IBD.